

Phospho-p21Cip1(S130) Antibody Blocking peptide
Synthetic peptide
Catalog # BP3187a**Specification****Phospho-p21Cip1(S130) Antibody Blocking peptide - Product Information**Primary Accession [P38936](#)**Phospho-p21Cip1(S130) Antibody Blocking peptide - Additional Information**

Gene ID 1026

Other Names

Cyclin-dependent kinase inhibitor 1, CDK-interacting protein 1, Melanoma differentiation-associated protein 6, MDA-6, p21, CDKN1A, CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP3187a](#) was selected from the region of human Phospho-p21Cip1-pS130. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Phospho-p21Cip1(S130) Antibody Blocking peptide - Protein Information**Phospho-p21Cip1(S130) Antibody Blocking peptide - Background**

p21 is a potent cyclin-dependent kinase inhibitor. It binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this protein is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. p21 can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. It was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation.

Phospho-p21Cip1(S130) Antibody Blocking peptide - References

Scott, S.A., et al., Leuk. Res. 28(12):1293-1301 (2004). Amini, S., et al., J. Biol. Chem. 279(44):46046-46056 (2004). Chen, T., et al., Cancer Res. 64(20):7412-7419 (2004). Sieburg, M., et al., J. Virol. 78(19):10399-10409 (2004). Giraud, S., et al., Oncogene 23(44):7391-7398 (2004).

Name CDKN1A

Synonyms CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WA

Function

May be involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. Binds to and inhibits cyclin- dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression. Functions in the nuclear localization and assembly of cyclin D-CDK4 complex and promotes its kinase activity towards RB1. At higher stoichiometric ratios, inhibits the kinase activity of the cyclin D- CDK4 complex. Inhibits DNA synthesis by DNA polymerase delta by competing with POLD3 for PCNA binding (PubMed:11595739). Plays an important role in controlling cell cycle progression and DNA damage- induced G2 arrest (PubMed:9106657).

Cellular Location

Cytoplasm. Nucleus

Tissue Location

Expressed in all adult tissues, with 5-fold lower levels observed in the brain

Phospho-p21Cip1(S130) Antibody Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)